Glycosylation is an essential post-translational modification, which determines the function of proteins and important processes such as inflammation. β-1,4-galactosyltransferase I (βGalT1) is a key enzyme involved in the addition of galactose moieties to glycoproteins. Intestinal mucins are glycoproteins that protect the gut barrier against invading pathogens and determine the composition of the intestinal microbiota. Proper glycosylation of mucus is important in this regard. By using ubiquitously expressing βGalT1 transgenic mice, we found that this enzyme led to strong galactosylation of mucus proteins, isolated from the gut of mice. This galactosylation was associated with a drastic change in composition of gut microbiota, as TG mice had a significantly higher Firmicutes to Bacteroidetes ratio. TG mice were strongly protected against TNF-induced systemic inflammation and lethality. Moreover, βGalT1 transgenic mice were protected in a model of DSS-induced colitis, at the level of clinical score, loss of body weight, colon length and gut permeability. These studies put βGalT1 forward as an essential protective player in exacerbated intestinal inflammation. Optimal galactosylation of N-glycans of mucus proteins, determining the bacterial composition of the gut, is a likely mechanism of this function.
References
[1]
Fu J, Wei B, Wen T, Johansson ME, Liu X, et al. (2011) Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. The Journal of clinical investigation 121: 1657–1666.
Thornton DJ, Rousseau K, McGuckin MA (2008) Structure and function of the polymeric mucins in airways mucus. Annu Rev Physiol 70: 459–486.
[4]
Macao B, Johansson DG, Hansson GC, Hard T (2006) Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin. Nat Struct Mol Biol 13: 71–76.
[5]
Kotani N, Asano M, Iwakura Y, Takasaki S (2001) Knockout of mouse beta 1,4-galactosyltransferase-1 gene results in a dramatic shift of outer chain moieties of N-glycans from type 2 to type 1 chains in hepatic membrane and plasma glycoproteins. The Biochemical journal 357: 827–834.
[6]
Hennet T (2002) The galactosyltransferase family. Cell Mol Life Sci 59: 1081–1095.
[7]
Asano M, Furukawa K, Kido M, Matsumoto S, Umesaki Y, et al. (1997) Growth retardation and early death of beta-1,4-galactosyltransferase knockout mice with augmented proliferation and abnormal differentiation of epithelial cells. EMBO J 16: 1850–1857.
[8]
Asano M, Nakae S, Kotani N, Shirafuji N, Nambu A, et al. (2003) Impaired selectin-ligand biosynthesis and reduced inflammatory responses in beta-1,4-galactosyltransferase-I-deficie？ntmice. Blood 102: 1678–1685.
[9]
Van Hauwermeiren F, Vandenbroucke RE, Libert C (2011) Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev 22: 311–319.
[10]
Xu D, Cui Z, Liu W, Tao R, Tao T, et al. (2011) Tumor necrosis factor-alpha up-regulates the expression of beta1,4-galactosyltransferase-I in human fibroblast-like synoviocytes. Inflammation 34: 531–538.
[11]
Yan M, Xia C, Niu S, Shao X, Cheng C, et al. (2007) The role of TNF-alpha and its receptors in the production of beta-1,4 galactosyltransferase I and V mRNAs by rat primary astrocytes. J Mol Neurosci 33: 155–162.
[12]
Yuan Q, Yang H, Cheng C, Li C, Wu X, et al. (2012) beta-1,4-Galactosyltransferase I involved in Schwann cells proliferation and apoptosis induced by tumor necrosis factor-alpha via the activation of MAP kinases signal pathways. Mol Cell Biochem 365: 149–158.
[13]
Niu S, Fei M, Cheng C, Yan M, Gao S, et al. (2008) Altered beta-1,4-galactosyltransferase I expression during early inflammation after spinal cord contusion injury. J Chem Neuroanat 35: 245–256.
[14]
Shen A, Chen J, Qian J, Zhu J, Hu L, et al. (2009) Elevated beta1,4-galactosyltransferase-I induced by the intraspinal injection of lipopolysaccharide. Glycoconj J 26: 19–31.
[15]
Dharmani P, Leung P, Chadee K (2011) Tumor necrosis factor-alpha and Muc2 mucin play major roles in disease onset and progression in dextran sodium sulphate-induced colitis. PLoS One 6: e25058.
[16]
Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, et al. (2005) Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 206: 260–276.
[17]
Van Hauwermeiren FAM, Karagianni N, Kranidioti K, Vandenbroucke RE, Loges S, et al. (2013) Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium. J Clin Invest May 15. pii: 65624. doi: 10.1172/JCI65624. [Epub ahead of print].
[18]
Podolsky DK, Isselbacher KJ (1984) Glycoprotein composition of colonic mucosa. Specific alterations in ulcerative colitis. Gastroenterology 87: 991–998.
[19]
Rhodes JM (1997) Colonic mucus and ulcerative colitis. Gut 40: 807–808.
[20]
Heazlewood CK, Cook MC, Eri R, Price GR, Tauro SB, et al. (2008) Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med 5: e54.
[21]
Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, et al. (2006) Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131: 117–129.
[22]
An G, Wei B, Xia B, McDaniel JM, Ju T, et al. (2007) Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. The Journal of experimental medicine 204: 1417–1429.
[23]
Stone EL, Ismail MN, Lee SH, Luu Y, Ramirez K, et al. (2009) Glycosyltransferase function in core 2-type protein O glycosylation. Mol Cell Biol 29: 3770–3782.
[24]
Shinzaki S, Iijima H, Fujii H, Kuroki E, Tatsunaka N, et al. (2012) Altered Oligosaccharide Structures Reduce Colitis Induction in Mice Defective in beta-1,4-Galactosyltransferase. Gastroenterology
[25]
Nyabi O, Naessens M, Haigh K, Gembarska A, Goossens S, et al. (2009) Efficient mouse transgenesis using Gateway-compatible ROSA26 locus targeting vectors and F1 hybrid ES cells. Nucleic Acids Res 37: e55.
[26]
Betz UA, Vosshenrich CA, Rajewsky K, Muller W (1996) Bypass of lethality with mosaic mice generated by Cre-loxP-mediated recombination. Curr Biol 6: 1307–1316.
[27]
Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA (2008) Mucins in the mucosal barrier to infection. Mucosal Immunol 1: 183–197.
[28]
Callewaert N, Geysens S, Molemans F, Contreras R (2001) Ultrasensitive profiling and sequencing of N-linked oligosaccharides using standard DNA-sequencing equipment. Glycobiology 11: 275–281.
[29]
Laroy W, Contreras R, Callewaert N (2006) Glycome mapping on DNA sequencing equipment. Nat Protoc 1: 397–405.
[30]
Vanhooren V, Dewaele S, Kuro OM, Taniguchi N, Dolle L, et al. (2011) Alteration in N-glycomics during mouse aging: a role for FUT8. Aging Cell 10: 1056–1066.
[31]
Vanhooren V, Dewaele S, Libert C, Engelborghs S, De Deyn PP, et al. (2010) Serum N-glycan profile shift during human ageing. Exp Gerontol 45: 738–743.
[32]
Vanhooren V, Laroy W, Libert C, Chen C (2008) N-glycan profiling in the study of human aging. Biogerontology 9: 351–356.
[33]
Vanhooren V, Liu XE, Franceschi C, Gao CF, Libert C, et al. (2009) N-glycan profiles as tools in diagnosis of hepatocellular carcinoma and prediction of healthy human ageing. Mech Ageing Dev 130: 92–97.
[34]
Moran AP, Gupta A, Joshi L (2011) Sweet-talk: role of host glycosylation in bacterial pathogenesis of the gastrointestinal tract. Gut 60: 1412–1425.
[35]
Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, et al. (2009) Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 15: 1183–1189.
[36]
Mariat D, Firmesse O, Levenez F, Guimaraes V, Sokol H, et al. (2009) The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol 9: 123.
[37]
Ayabe T, Satchell DP, Wilson CL, Parks WC, Selsted ME, et al. (2000) Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol 1: 113–118.
[38]
Ayabe T, Satchell DP, Pesendorfer P, Tanabe H, Wilson CL, et al. (2002) Activation of Paneth cell alpha-defensins in mouse small intestine. J Biol Chem 277: 5219–5228.
[39]
Vandenbroucke RE VI, Van Hauwermeiren F, Van Wonterghem E, Wilson C, Libert C (2013) Pro-inflammatory effects of matrix metalloproteinase 7 in acute inflammation. Mucosal Immunology In press.
[40]
Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, et al. (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234: 470–474.
[41]
Ma TY, Boivin MA, Ye D, Pedram A, Said HM (2005) Mechanism of TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol 288: G422–430.
[42]
Marchiando AM, Shen L, Graham WV, Weber CR, Schwarz BT, et al. (2010) Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo. J Cell Biol 189: 111–126.
[43]
Vereecke L, Sze M, Mc Guire C, Rogiers B, Chu Y, et al. (2010) Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. The Journal of experimental medicine 207: 1513–1523.
[44]
Libert C, Brouckaert P, Shaw A, Fiers W (1990) Induction of interleukin 6 by human and murine recombinant interleukin 1 in mice. Eur J Immunol 20: 691–694.
[45]
Takahashi N, Vanlaere I, de Rycke R, Cauwels A, Joosten LA, et al. (2008) IL-17 produced by Paneth cells drives TNF-induced shock. The Journal of experimental medicine 205: 1755–1761.
[46]
Van Molle W, Wielockx B, Mahieu T, Takada M, Taniguchi T, et al. (2002) HSP70 protects against TNF-induced lethal inflammatory shock. Immunity 16: 685–695.
[47]
Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, et al. (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105: 16731–16736.
[48]
Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, et al. (1994) Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107: 1643–1652.
[49]
Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, et al. (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694–702.
[50]
Iwaya H, Maeta K, Hara H, Ishizuka S (2012) Mucosal permeability is an intrinsic factor in susceptibility to dextran sulfate sodium-induced colitis in rats. Exp Biol Med (Maywood)
[51]
Vandenbroucke RE, Dejonckheere E, Lodens S, Van Hauwermeiren F, De Rycke R, et al. (2013) MMP13 modulates intestinal epithelial barrier integrity in inflammatory diseases. EMBO Mol Med in press.
[52]
Kukuruzinska MA, Lennon K (1998) Protein N-glycosylation: molecular genetics and functional significance. Crit Rev Oral Biol Med 9: 415–448.
[53]
Ohtsubo K, Marth JD (2006) Glycosylation in cellular mechanisms of health and disease. Cell 126: 855–867.
[54]
Raman R, Raguram S, Venkataraman G, Paulson JC, Sasisekharan R (2005) Glycomics: an integrated systems approach to structure-function relationships of glycans. Nat Methods 2: 817–824.
[55]
Furukawa K, Sato T (1999) Beta-1,4-galactosylation of N-glycans is a complex process. Biochim Biophys Acta 1473: 54–66.
[56]
Rini J, Esko J, Varki A (2009) Glycosyltransferases and Glycan-processing Enzymes.
[57]
Varki A, Lowe JB (2009) Biological Roles of Glycans.
[58]
Mori R, Kondo T, Nishie T, Ohshima T, Asano M (2004) Impairment of skin wound healing in beta-1,4-galactosyltransferase-deficient mice with reduced leukocyte recruitment. Am J Pathol 164: 1303–1314.
[59]
Strugala V, Allen A, Dettmar PW, Pearson JP (2003) Colonic mucin: methods of measuring mucus thickness. Proc Nutr Soc 62: 237–243.
[60]
Rozee KR, Cooper D, Lam K, Costerton JW (1982) Microbial flora of the mouse ileum mucous layer and epithelial surface. Appl Environ Microbiol 43: 1451–1463.
[61]
Littman DR, Pamer EG (2011) Role of the commensal microbiota in normal and pathogenic host immune responses. Cell Host Microbe 10: 311–323.
[62]
Sando L, Pearson R, Gray C, Parker P, Hawken R, et al. (2009) Bovine Muc1 is a highly polymorphic gene encoding an extensively glycosylated mucin that binds bacteria. J Dairy Sci 92: 5276–5291.
[63]
Schroers V, Van Der Marel M, Steinhagen D (2008) Influence of carp intestinal mucus molecular size and glycosylation on bacterial adhesion. Dis Aquat Organ 81: 135–142.
[64]
Magalhaes A, Gomes J, Ismail MN, Haslam SM, Mendes N, et al. (2009) Fut2-null mice display an altered glycosylation profile and impaired BabA-mediated Helicobacter pylori adhesion to gastric mucosa. Glycobiology 19: 1525–1536.
[65]
Sonnenburg JL, Xu J, Leip DD, Chen CH, Westover BP, et al. (2005) Glycan foraging in vivo by an intestine-adapted bacterial symbiont. Science 307: 1955–1959.
[66]
Keshav S (2006) Paneth cells: leukocyte-like mediators of innate immunity in the intestine. J Leukoc Biol 80: 500–508.
[67]
Groux-Degroote S, Krzewinski-Recchi MA, Cazet A, Vincent A, Lehoux S, et al. (2008) IL-6 and IL-8 increase the expression of glycosyltransferases and sulfotransferases involved in the biosynthesis of sialylated and/or sulfated Lewisx epitopes in the human bronchial mucosa. The Biochemical journal 410: 213–223.
[68]
Wu YM, Nowack DD, Omenn GS, Haab BB (2009) Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells. J Proteome Res 8: 1876–1886.
[69]
Shinzaki S, Iijima H, Nakagawa T, Egawa S, Nakajima S, et al. (2008) IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease. Am J Gastroenterol 103: 1173–1181.
[70]
George SH, Gertsenstein M, Vintersten K, Korets-Smith E, Murphy J, et al. (2007) Developmental and adult phenotyping directly from mutant embryonic stem cells. Proc Natl Acad Sci U S A 104: 4455–4460.
[71]
Van Snick J, Cayphas S, Vink A, Uyttenhove C, Coulie PG, et al. (1986) Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci U S A 83: 9679–9683.
